Pre-made Zalifrelimab benchmark antibody ( Whole mAb, anti-CTLA4/CTLA-4 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-636

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-636 Category Tag

Product Details

Pre-Made Zalifrelimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Zalifrelimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody

INN Name

Zalifrelimab

Target

CTLA4

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2018

Companies

4-Antibody,Ludwig Institute for Cancer Research,Agenus,Recepta biopharma

Conditions Approved

NA

Conditions Active

Non-small cell lung cancer,Cervical cancer,Cancer,Haemangiosarcoma,Soft tissue sarcoma,Sold tumours

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

CTLA4

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide